Introduction to Psychedelic-assisted Therapy​

Laying the foundations, together

Our continuing education credited introductory psychedelic-assisted therapy training course is designed to help practicing psychologists, psychiatrists, and other medical professionals gain an understanding of psychedelic-assisted therapy. 

$1197 USD

$957 USD

*Discount ends August 15, 2022

About this course

This course begins by re-defining the psychiatric model from one of “chemical imbalance” to one rooted in the mind-body-spirit dynamic. With roots in contemporary medical and mental health research, this training program also provides the historical foundation from which psychedelic medicines developed. The didactic course material will cover the various psychedelic medicines currently in use, including an emphasis on psilocybin, MDMA, LSD, iboga, ayahuasca, and ketamine.

This introductory course will also explore how psychedelic-assisted therapy can be integrated into and enhance existing therapeutic modalities, such as internal family systems (IFS), cognitive-behavioural therapy (CBT), somatic therapy, and eye movement desensitization and reprocessing (EMDR).

Lesson 1

Psychedelic-assisted Psychotherapy

Lesson 2

History of Psychedelics

Lesson 3

Ethics in Psychedelic Therapy

Lesson 4

Iboga in Addictions and Other Therapy

Lesson 5


Lesson 6
Lesson 7

MDMA: Trials and Training

Lesson 8

Ketamine: Insights from the Emergency Department

Lesson 9

LSD: Past, Present, and Future

Lesson 10

Psychedelic-assisted Psychotherapy and Wellness Enhancement: An Excellent Duo

Lesson 11

Death, Dying and Psychedelics

Lesson 12

Manual of Psychedelic Guides

Lesson 13

A Relational Model of Psychedelic Integration

Lesson 14

Self-Care for the Psychedelic Guide

Hear what our students have to say

This program has not only done a masterful job of setting the foundations for psychedelic-assisted therapy, but also helped connect participants with like-minded health providers and fostered a continued interest in exploring this needed healing modality at an even deeper level.



Great format of watching presentations ahead of time for the Q&A’s and then speaking to the amazing presenters about their experiences. Wonderful to connect with other therapists and interested individuals through breakout groups.



The richness of the experience, expertise and discussion was deeply meaningful. Thank you ATMA.



So informative and a must if you are interested in becoming a psychedelic therapist.



It’s wonderful to be on live Zoom calls with so many amazing teachers. Thank you all, so much gratitude for this space!



Ready to start learning?

Classes are open for September 2022 and seats are filling fast. Don’t miss your chance to get started early – Register Now!

Frequently Asked Questions

This training is designed to help practicing counsellors, psychologists, psychiatrists and medical professionals gain a basic understanding of psychedelic therapy, as well as those generally interested in psychedelic-assisted therapy. It is not intended to replace what you feel already works, but to provide you with additional, science-based tools to enhance your current practice.

Currently, there are no in-person events, however the live weekly sessions provide for valuable community building.

Our advanced course will provide in-person experiential training.

We do not offer refunds once you have paid however, we will work with you if situations prevent you from attending the course you paid for.

Our payment plans allow you to pay for your course’s tuition in a series of equal payments. To learn more, click here to book a consultation with one of our academic advisory team members.

Our CE credits are valid in Canada.

Scroll to Top

Due to the unique nature of psychedelic-assisted therapy, the clinicians providing such a service have a specific set of needs in regards to preventing professional burnout. This module will begin by defining self-care and exploring professional burnout as it relates to psychedelic-assisted therapists, and will proceed by exploring the unique considerations for psychedelic-assisted therapy vs. traditional psychotherapy. Additionally, tools for self-care in relation to these considerations will be examined. We will conclude by providing suggestions for aftercare practices and how one can utilize community to create containment.

In this presentation, a model of psychedelic integration will be presented, focusing on the capacity for increased relational intimacy as a critical measure of post-psychedelic experience. One model describes how early trauma shapes negative beliefs about the self, others, and reality, which in turn generate inaccurate interpretations in adulthood. As a result of psychedelic therapy, these Core Unconscious Beliefs may be brought to conscious awareness for reconsideration and re-decision, which in turn creates space to evolve in relational intimacy.

For many years, Mark Haden has been involved in psychedelic-assisted therapy through MAPS Canada and other avenues. Through the combination of his vast experience and collaboration with other contributors, he has developed an in-depth manual for psychedelic therapists. This content will be the backbone of the evening as he shares what it takes to be a competent and effective guide for this work.

Numerous clinical trials have resulted in increased awareness regarding the use of psychedelics in easing end-of-life distress in patients facing terminal illnesses; these trials have been conducted across different countries and over a span of many years. Further, Canada’s recent approvals of Section 56 Exemption applications has demonstrated the profound impact that psychedelics have in producing meaningful end-of-life experiences. In this module, follow the story of one woman’s journey, as well as testimonials of key researchers – featuring a live Q&A with Dr. Anthony Bossis, a leading psychedelic researcher at NYU.

Psychedelic-assisted therapy and wellness enhancement are both areas of immense interest relating to mental health. This module will examine these areas, offer a robust discussion on how they are linked, and how they can be combined in the pursuit of attenuating our patients’ suffering and facilitating their healing.

This presentation will explore the use of LSD in the context of its therapeutic potential for the treatment of a variety of psychiatric disorders. Historical publications as well as recent anecdotal reports will be explored; both perspectives provide valuable lessons pertaining to future work with LSD.

Ketamine is becoming the most widely used mind-altering medicine, which has extended beyond pain management into the realm of mental health applications. There are many indications for which it is used, employing several distinct routes of administration. The benefits, challenges, and means in which it can be incorporated into a therapist’s practice will be explored in this module.

This talk will review the history of clinical use of ketamine, from anesthetic to antidepressant, as well as the latest uses that have been discovered for this old drug.

This module will cover the applications of MDMA in psychotherapy, with a primary focus on a clinical trial that used the PTSD protocol to treat eating disorders.

Mushrooms, or more specifically psilocybin (the psychoactive ingredient in mushrooms), is one of the most researched psychedelics in modern medicine. This lesson will explore psilocybin’s pharmacology, indications, and effectiveness. We will also examine current psilocybin trials and studies that are being conducted, which demonstrate its healing benefits in a variety of applications.

From banned to breakthrough: MDMA’s transformation from an illicit substance to a breakthrough treatment for PTSD.

Ibogaine is the psychoactive ingredient of Iboga, a root indigenous to Gabon in Africa. It has both traditional uses, as well as clinical applications primarily related to addiction. Through a company he operates in B.C. called Liberty Root, Trevor Millar has been using Iboga to help treat individuals, and he will be discussing this medicine’s potential and the current uses of this plant.

The paradigm shift in mental health is underway, and psychedelic medicine plays an integral role in this change! For this shift to continue to expand and strengthen, it is imperative that psychedelic medicine is accompanied with scientific rigour and vigorous adherence to ethical standards. Megan McElheran will discuss ethical decision-making as it applies to psychedelic-assisted therapy. We will review the current status of regulations and ethical guidelines in Canada, and explore how to approach ethical decision-making as psychedelic-assisted therapies are incorporated into clinical practice.

Did you know the word “psychedelic” was coined right here in Canada? Join Dr. Erika Dyck as she discusses how the history of psychedelics is shaping this new psychedelic renaissance, and how we can avoid some of the pitfalls that occurred in the first wave of psychedelic therapy in the 60s and 70s. The depth of knowledge Dr. Dyck possesses in this field is second-to-none, and her understanding of Canadian psychedelic history will shape the rest of this course work.

What is psychedelic-assisted therapy? What is the psychedelic experience? This first overview session will cover the basic elements regarding why psychedelic-assisted therapy is a unique therapeutic process that lies outside of any traditional therapy, but why it is still important to have knowledgeable and loving therapists drive the renaissance in which we find psychedelics.